World health, IP, trade bodies launch Covid platform

 

NUT Desk- GENEVA: The heads of the global health, IP and trade agencies on Thursday announced a joint platform to help countries plug the gaps in accessing Covid-19 vaccines, treatments and technologies.

The WHO member countries of the World Health Organization (WHO), the World Intellectual Property Organization (WIPO) and the World Trade Organization (WTO) said countries would be able to access expertise in places where the three fields cross over in battling the pandemic.

WHO chief Tedros Adhanom Ghebreyesus, WIPO head Daren Tang and WTO director-general Ngozi Okonjo-Iweala met on June 15,

when they agreed to work together more closely to support access to medical technologies to tackle the coronavirus crisis. “We will implement a joint platform for tripartite technical assistance to countries relating to their needs for Covid-19 medical technologies,” they said in a joint statement.

The platform will provide “a one-stop shop that will make available the full range of expertise on access, IP and trade matters provided by our organisations, and other partners”, in a coordinated way. They said it would support states in assessing and prioritising their unmet needs for Covid-19 vaccines, medicines and other related technologies. It would also help them make full use of all available options to access such tools, including through coordinating with other countries going through similar challenges.

The WHO member countries also announced a series of workshops to boost the flow of information in the push to get equitable access to Covid-19 technology. Sharing technology is an increasingly hot topic in the fight against the coronavirus pandemic.

who member countries
World health, IP, trade bodies launch Covid platform

The WHO member countries has been calling for a temporary waiver on IP rights for Covid-19 vaccines in a bid to boost production around the world and thereby increase access to doses in poorer countries, where immunisation rates are way lower. Talks are inching forward at the WTO after South Africa and India put forward a proposal in October. Agreements at the global trade body require the consensus of all member states.

UK man tested positive for virus for 10 straight months

LONDON: A 72-year-old British man tested positive for coronavirus for 10 months in what is thought to be the longest recorded case of continuous infection, researchers said on Thursday. Dave Smith, a retired driving instructor from Bristol in western England, said he tested positive 43 times, was hospitalised seven times and had made plans for his funeral. “I”d resigned myself, I”d called the family in, made my peace with everybody, said goodbye,”, he told BBC television. His wife, Linda, who quarantined with him at home, said: “There was a lot of times when we didn”t think he was going to pull through. It”s been a hell of a year”. Ed Moran, a consultant in infectious diseases at the University of Bristol and North Bristol NHS Trust, said Smith “had active virus in his body” throughout.

50pc of Kasur cops found drugs `positive`

KASUR: As many as 24 out of 48 policemen selected for drug test in the district were found `positive` on Tuesday.

The drug tests of police officials are being conducted on the orders of the prime minister to bring reforms in the police department.

The Punjab inspector general of police (IGP) has issued directives to conduct the drug test of of ficialsranging from constables to the Police Service of Pakistan (PSP) officers.

Samples of 48 of ficials, including constables and assistant subinspectors(ASIs),werecollectedin the district a couple of days back for the drug test. Interestingly, no policeman above the ASI rank was listedforthe drugtest.

According to the district police, the officials were selected for the drug test on the basis of internal intelligence reports.

The district police got the samples tested from a private lab, instead of any public hospital`s laboratory.

Explaining the choice, District Police Officer Imran Kishwar said that private lab was more reliable as compared to those of public sector hospitals. As per sources, a majority of the policemen found using drugs were constables.

A police of ficial, requesting anonymity, said the process of drug test was similar to that used for declaring common suspects as addicts during the course of investigation at the police station level.

Pakistan-Facebook collaboration to kill Covid-19

ISLAMABAD: Pakistan and Facebook have partnered to fight Covid-19 as the world`s prominent social media platform has provided Marketing Partner Support and Ad Credits for campaigns against the deadly virus and helped the government increase its engagement rates with the public on these posts.

As part of these campaigns, Facebook and some ministries focused on creating videos and messages for boosting `vaccine confidence` amongst the public.

The messaging campaigns helped the Ministry of Health increase its total number of page likes to 470,000, increasing the government`s ability to connect with the people and provide information to its stakeholders.

In a statement, Facebook has said it is important to come together as a community to protect each other through credible health information and support vaccine confidence in the community.

As Covid-19 vaccines are becoming morereadily available to larger groups, Facebook launched its new profile frames in partnership with the Ministry of Health that allow users to share their support for getting vaccinated with their family and friends.

Lowest Covid casualty rate in eight months

ISLAMABAD:The lowest number of deaths and cases of coronavirus infections was reported on Tuesday in the country for over eight months.

According to the National Command and Operation Centre (NCOC), 27 deaths and 663 cases of Covid-19 were reported in a single day. On October 20 last year, 660 cases were reported.

The number of active cases, which had topped 90,000 in April, stood at 33,452 as of June 22, while 271 ventilators were in use across the country.

Meanwhile, several people complained of errors in vaccination data and expressed fears this might become a problem for them in future.

However, an official of the Ministry of National Health Services (NHS) claimed that over 13 million doses had been administered and only a few hundred persons faced problems regarding data entry.

He urged them to contact the vaccination centre or the helpline to get their issue resolved. A man told media that he had received the first dose of Sinovac on May 20 and waited for four weeks to getthe second dose.

`As vaccine was not available across the country, I waited for a while. Later, I checked my status by sending SMS to 1166, but was shocked to see that according to it I got my second dose on June 17,` he said.

Another man lodged a complaint with the Ministry of NHS that the vaccination certificate downloaded from the official website showed that he got his second shot well before the first one.

Famine threatens 41m masses in 43 countries including Afghanistan: UN

UNITED NATIONS: Famine is knocking at the doors of 41 million people in 43 countries, including Afghanistan, according to a UN report released on Tuesday.

The report by the World Food Programme (WFP) warned that the threat of famine had increased dramatically over the past two years from 27 million in 2019 to 41 million this year.

The UN agency has sought urgent funding and humanitarian access to those in need.

The report advocated `diversification of supply corridors` in Afghanistan, `mitigating over-reliance on existing corridors with Pakistan to avoid operational delays`.

In Afghanistan, `poor rainfall has affected most parts of the country since November, threatening rainfed wheat-crop production, the report warned, It added that `water availability for spring and summer crops could also be lim-ited due to reduced snowmelt in some basins`.

`I am heartbroken at what we`re facing in 2021,` said WFP chief David Beasley while describing the situation as `just tragic` because `these are real people with real names`.

According to WFP,584,000 people are already experiencing famine-like conditions in Ethiopia, Madagascar, South Sudan and Yemen.

Nigeria and Burkina Faso are also of particular concern as they have pockets where famine-like conditions are present.

`In Somalia in 2011, 260,000 people died of hunger and by the time the famine was actually declared half of that number had already died,` Mr.

Beasley recalled. `We can`t debate the numbers to death when people need our help now.

The report blamed conflict, climate change and currency depreciation for famine-like situations in many countries.

1.55m doses of Sinovac arrive, 5m more next month

ISLAMABAD: As complaints of shortage of Covid-19 vaccines were being received from all federating and administrative units of the country, 1.55 million doses of Sinovac vaccine reached here from China on Sunday.

Half of the consignment was offloaded at Islamabad airport after which a special flight took off for Karachi to deliver the remaining doses ofthe vaccine there. Federal Minister for Planning, Development and Special Initiatives Asad Umar, who is also the head of NCOC, has claimed in a tweet that around 5m more doses of the vaccine will arrive by the end of the current month.
The National Command and Operation Centre (NCOC) has claimed that 2m to 3m more doses of Covid-19 vaccine will arrive by the end of the current month.

According to an NCOC statement, a special consignment of Sinovac vaccine comprising 1.55 million doses arrived at the Islamabad airport through a special PIA flight.

`This is part of a planned contracted quantity purchased from China. China, as a time-tested friend of Pakistan, has taken special measures to ensure uninterrupted supply of the vaccine to Pakistan.

`Another consignment of 2 to 3 million doses of the Chinese vaccine will be reaching Pakistan next week followed by continued supply. Measures are in place to transport these vaccines to all federating unit s according to their requirement,` the statement added.

A spokesman for the Pakistan International Airlines said a PIA flight (PK-6852) carrying the shipment ofdoses of Sinovac vaccine landed at the Islamabad International Airport at 11.30am.

He said a special PIA flight would bring 2m doses of the vaccine from China on June 22 as the national nag carrier had been using Boeing 777 for the relief operations.

Pakistan’s major political parties demand audit of Covid funds

ISLAMABAD: Expressing concerns over the reports coming from various parts of the country regarding shortage of Covid-19 vaccine, major opposition parties the Pakistan Muslim League-Nawaz (PML-N) and Pakistan Peoples Party (PPP) on Sunday accused the government of committing a `criminal negligence` and called for audit of the coronavirus funds.

PML-N president and Leader of the Opposition in the National Assembly Shehbaz Sharif asked the government to stop playing with the lives of people and make arrangements for immediate supply of vaccines keeping in view the fact that the total population of Pakistan is 220 million.

`The government must change its shallow-minded approach of ordering a few million doses and working with the vaccine supplies given to Pakistan as charity. The una-vailability of the vaccine is another proof of the government`s criminal negligence and incompetence,` the PML-N president said in a statement on the day Pakistan received another consignment of over 1.5 million doses of Covid-19 vaccine from China.

Mr Sharif said the opposition had repeatedly warned that failure to ensure timely vaccination would not protect the lives of people from the deadly virus. The government, he said, was erring and delaying the supply of vaccines in the same way it had handled the supply of LNG which led to massive losses. But this time round it was a matter of life and death ofPakistanis,he stressed.

Mr Sharif alleged that the `opportunists in this corrupt government` who had already bagged billions of rupees in illegal profit in sugar and flour crises were now trying to seize this opportunity as well to make money at the cost of lives. `It is unfortunate that the government is showing the most serious display of criminal negligence in the matter of people`s lives.

Vaccine shortage proves govt inefficient: Shehbaz

LAHORE: Pakistan Muslim League-Nawaz (PMLN) President and National Assembly Opposition Leader Shehbaz Sharif has expressed grave concern and alarm over the unavailability of COVID-19 vaccine in the country.

In a statement, issued here on Sunday, Shehbaz said the government should make arrangements for immediate supply of corona vaccine and should not play with the lives of people.

He said the government should chalk out plan by keeping in mind the population of Pakistan in this regard.

“The government must change its shallow-minded approach of ordering a few million doses and working with the vaccine supplies given to Pakistan as charity. The unavailability of the corona vaccine is another proof of the government’s criminal negligence and incompetence”, Shehbaz said.

He said the opposition has repeatedly warned that failure to ensure timely vaccinations will not protect the lives of the people from the deadly virus. The government is erring and delaying the supply of vaccines the same way it handled the supply of LNG which led to massive losses, but this time round it is a matter of life and death of Pakistanis, he stressed.

The opportunists, in this corrupt government that bagged billions in illegal profit in sugar and flour crisis, were trying to seize this opportunity as well to make money at the cost lives, he pointed out. It is unfortunate that the government is showing the most serious display of criminal negligence in the matter of people’s lives, he said.

Pfizer and BioNTech to Supply Pakistan with 13 million doses of their Vaccine to Combat COVID-19

  • Supply to be provided over the course of 2021
  • Agreement is part of Pfizer’s and BioNTech’s global commitment to help address the COVID-19 pandemic

Lahore (Muhammad Yasir) Pfizer Pakistan and BioNTech SE today announced an agreement with the National Disaster Management Authority, Government of Pakistan to supply 13 million doses of their COVID-19 Vaccine (BNT162b2). Deliveries are planned during course of 2021.

“We are deeply honored to work with the Pakistan government and to marshal our scientific and manufacturing resources toward our shared goal of bringing a COVID-19 vaccine to the people of Pakistan as quickly as possible,” said Syed Muhammad Wajeehuddin, Country Manager Pfizer Pakistan. “In the face of this global health crisis, Pfizer’s purpose – breakthroughs that change patients’ lives – has taken on an even greater urgency. Our hope is that our vaccine will help make this happen.”

“I would like to thank the Pakistan government for its support and putting trust in our ability to develop a vaccine that, we believe, has the potential to help address this global pandemic threat. Our goal remains to deliver a global supply of a well tolerated and effective COVID-19 vaccine for many people around the world, as quickly as we can,” said Sean Marett, Chief Business and Chief Commercial Officer at BioNTech.

Pfizer and BioNTech aim to manufacture more than 3 billion doses of their COVID-19 vaccine globally in total by the end of 2021, assuming updated six dose labeling, continuous process improvements, expansion at current facilities and contingent upon adding new suppliers and contract manufacturers.

The vaccine, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer, and the marketing authorization holder is BioNTech in the United States, Europe, U.K., Canada, and other countries.

About the Study

The Phase 3 clinical trial of BNT162b2, which is based on BioNTech’s proprietary mRNA technology, began in late July 2020 and completed enrolled in January 2021 at more than 46,000 participants. A breakdown of the diversity of clinical trial participants can be found at https://www.pfizer.com/science/coronavirus/ vaccine from approximately 150 clinical trials sites in the U.S., Germany, Turkey, South Africa, Brazil and Argentina. Participants will continue to be monitored for long-term protection and safety for an additional two years after their second dose.

About Pfizer: Breakthroughs That Change Patients’ Lives

Pfizer has been working for the health and wellbeing of patients in Pakistan for more than 60 years. Our business in Pakistan is part of the global Pfizer Inc. operations, first founded in 1849 in New York, USA. Pfizer Pakistan reach for patients is 20 million of 200 million At Pfizer Pakistan, we provide access to safe, innovative and affordable medicines to millions of Pakistanis. Having a portfolio of medicines that prevent, treat and cure diseases across a range of therapeutic areas allows Pfizer Pakistan to enjoy the reputation of being a leading drug maker in the country. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our operations in Pakistan, please visit us at www.pfizer.com.pk.

About BioNTech

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.

BioNTech Forward-looking Statements

This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer regarding a COVID-19 vaccine; our expectations regarding the potential characteristics of BNT162b2 in our Phase 2/3 trial and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on trial data of BNT162b2 in our Phase 2/3 trial; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimate for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.

For a discussion of these and other risks and uncertainties, see BioNTech’s Quarterly Report for the Three and Nine Months Ended September 30, 2020, filed as Exhibit 99.2 to its Current Report on Form 6-K filed with the SEC on November 10, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.